Clinical trials: Chronic Disease
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL.
- Trial name
- NCT03331198
- Testing
- JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
- Where
- 84 sites in United States, Canada
- Volunteers
- 320 people
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene
Chronic Kidney Diseases
everlinQ Endovascular Access System Enhancements (EASE) Study
Prospective, single-center study to evaluate the everlinQ System when used to create an endoAVF in hemodialysis patients.
- Trial name
- NCT03708770
- Testing
- everlinQ endoAVF System
- Volunteers
- 32 people
- Sponsor
- C. R. Bard
Respiratory Disorders
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.
The purpose of this Phase II study is to assess the safety, reactogenicity and immunogenicity of the investigational Non-typeable Haemophilus influenzae (NTHi) vaccine in patients with moderate and severe persistent airflow…
- Trial name
- NCT02075541
- Testing
- NTHi-10-AS01E
- Where
- 14 sites in Sweden, United Kingdom
- Volunteers
- 145 people
- Sponsor
- GlaxoSmithKline
Hepatitis C, Chronic
A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4
This 6-arm study will assess the efficacy and safety of RO5024048 (R7128) in combination with the approved doses of Pegasys (180micrograms sc weekly) + Copegus (1000/1200mg po daily) (SOC), versus SOC in treatment-naive patients…
- Trial name
- NCT00869661
- Testing
- Copegus, Pegasys, RO5024048
- Where
- 66 sites in United States, Australia and 8 more
- Volunteers
- 413 people
- Sponsor
- Hoffmann-La Roche
Anemia, Kidney Disease
Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease
The purpose of this study is to evaluate whether the efficacy of darbepoetin alfa SF is equivalent to that of darbepoetin alfa RB for the treatment of anemia in patients with chronic kidney disease (CKD) receiving hemodialysis.
- Trial name
- NCT00121602
- Testing
- Darbepoetin Alfa
- Volunteers
- 446 people
- Sponsor
- Amgen
Asthma, COPD
The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.
This study is a Phase IIa, randomized, placebo-controlled, double-blind, 2-way crossover, 2-center (conducted in EU; The Netherlands) study in male and female subjects with stable, mild HDM-allergic asthma.
- Trial name
- NCT03858686
- Testing
- FP-025 capsules
- Where
- 2 sites in Netherlands
- Volunteers
- 27 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Anemia of Chronic Kidney Disease
CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis
The aim of this study was to compare and evaluate efficacy and safety of intravenous CKD-11101 versus Darbepoetin alfa in patients who have renal anemia receiving hemodialysis.
- Trial name
- NCT03428594
- Testing
- CKD-11101, NESP
- Volunteers
- 403 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Coronary Artery Disease
A Trial to Evaluate Efficacy of Heart-protecting Musk Pill
Title: A randomized, double-blind, multi-centered, placebo-controlled trial to examine effects of of Heart-protecting Musk Pill on clinical outcomes in patients with chronic stable coronary artery disease Objective: To examine…
- Trial name
- NCT01897805
- Testing
- Heart-protecting Musk Pill
- Where
- 98 sites in China
- Volunteers
- 2,700 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
End Stage Renal Disease
Clinical Performance Comparison of 2 THERANOVA 400 Dialyzer Prototypes in HD With High-Flux Dialyzers in HD and hv HDF Mode
The study investigates the performance of a new dialyzer (Theranova 400) containing a membrane with increased pore sizes. The performance will be determined by the removal of middle molecules (with different molecular size) from…
- Trial name
- NCT02377622
- Testing
- THERANOVA 400 dialyzer prototype AA, THERANOVA 400 dialyzer prototype BB, FX CorDiax 80 Dialyzer
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Vantive Health LLC
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
The purpose of this study is to assess the safety and effectiveness in the real-world setting among participants who are treated with Azacitidine in accordance with the China Product Label.
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
- Trial name
- DIM Vidaza (NCT05218902)
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Bristol-Myers Squibb
Renal Insufficiency, Chronic
TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)
The purpose of this study is to determine the recommended dose of the sustained-release form of BPS (TRK-100STP low dose or high dose) in Japanese patients with CRF (Primary glomerular disease/nephrosclerosis).
- Trial name
- NCT02480751
- Testing
- Beraprost
- Volunteers
- 113 people
- Sponsor
- Toray Industries, Inc
Chronic Obstructive Pulmonary Disease (COPD)
A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD
This is a long-term safety trial of 48 weeks. Eligible subjects will enter the 48-week, open-label treatment period to receive one of two treatments (SUN-101 given as 50 mcg twice a day or Spiriva® [tiotropium] given as 18 mcg…
- Trial name
- GOLDEN-5 (NCT02276222)
- Testing
- SUN-101 50 mcg BID eFlow (CS) nebulizer, Spiriva® 18 mcg QD Handihaler
- Where
- 118 sites in United States, Czechia and 2 more
- Volunteers
- 1,087 people
- Sponsor
- Sunovion Respiratory Development Inc.
Hepatitis C, Chronic
A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels
Participants with Chronic Hepatitis C (CHC) and normal ALT, who have been under treatment with peginterferon alfa-2a and ribavirin for at least 4 weeks, will be enrolled into this non-interventional, open-label study.
- Trial name
- NCT02726022
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 10 sites in Greece
- Volunteers
- 114 people
- Sponsor
- Hoffmann-La Roche
Atopic Dermatitis
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
- Trial name
- NCT03568331
- Testing
- Tradipitant
- Where
- 70 sites in United States
- Volunteers
- 375 people
- Sponsor
- Vanda Pharmaceuticals
Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
This is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug (QPI-1007) will be given to all patients who participate.
- Trial name
- NCT01064505
- Testing
- QPI-1007 at various doses
- Where
- 28 sites in United States, Israel
- Volunteers
- 48 people
- Sponsor
- Quark Pharmaceuticals
Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD
Cardiac Safety Study
- Trial name
- CARSAF (NCT01584505)
- Testing
- CHF1535 + CHF5992 dose 1 BID, CHF1535 + CHF5992 dose2 BID, CHF1535 daily dose
- Where
- 6 sites in Bulgaria, Germany and 4 more
- Volunteers
- 191 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Kidney Disease
A Study of PRT-201 Administered After Arteriovenous Graft (AVG) Creation in Patients With Chronic Kidney Disease
PRT-201 is a recombinant human type-I pancreatic elastase intended for local, long-lasting dilation of the AVG venous anastomosis and outflow vein.
- Trial name
- PRT-201-102 (NCT01001351)
- Testing
- PRT-201
- Where
- 16 sites in United States
- Volunteers
- 89 people
- Sponsor
- Proteon Therapeutics
Herpes Labialis
Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection
This is a phase II, double-blind, randomised, controlled, multicentre trial of topical HDIT101 versus placebo. HSV-1-positive patients with at least 6 orolabial herpes lesions in the last 12 months can be included.
- Trial name
- MATCH-1 (NCT04539483)
- Testing
- HDIT101 (blinded therapy), Photo documentation of orolabial herpes lesions, Completion of questionnaires (patient-reported outcomes)
- Where
- 5 sites in Germany
- Volunteers
- 761 people
- Sponsor
- Heidelberg ImmunoTherapeutics GmbH
Chronic Obstructive Pulmonary Disease
The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
This study compared the effect of indacaterol (300 μg once daily [od]) on exercise endurance with that of placebo in patients with moderate to severe chronic obstructive pulmonary disease.
- Trial name
- NCT00620022
- Testing
- Indacaterol 300 μg
- Where
- 20 sites in United States, Belgium and 4 more
- Volunteers
- 90 people
- Sponsor
- Novartis
Hepatitis B
Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil in Children and Adolescents With HBV
Open-label study of the pharmacokinetics of adefovir dipivoxil in children and adolescents infected with chronic hepatitis B.
- Trial name
- NCT00645294
- Testing
- Adefovir dipivoxil
- Where
- 10 sites in Belgium, Germany and 2 more
- Volunteers
- 47 people
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.